Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events

Thrombosis Research

Volumn 123, Issue 1, 2008, Pages 67-71

  Dentali, Francesco ^a   Riva, Nicoletta ^a   Gianni, Monica ^a   Malato, Alessandra ^b   Bozzato, Silvia ^a   Bernasconi, Matteo ^c   Tuttolomondo, Antonino ^d   Romano, Adele ^d   Pinto, Antonio ^d   Siragusa, Sergio ^b   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Psychiatric Department   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; VENOUS THROMBOEMBOLISM;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 44949140824     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.01.009     Document Type: Article

References (25)

1. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., Leizorovicz A., Nguyen H., Olsson C.G., Turpie A.G., and Weisslinger N.A. Comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341 (1999) 793-800
2. Leizorovicz A., Cohen A.T., Turpie A.G., Olsson C.G., Vaitkus P.T., and Goldhaber SZ. PREVENT Medical Thromboprophylaxis Study Group. Randomized, no prophylaxis-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 (2004) 874-879
3. Mismetti P., Laporte-Simitsidis S., Tardy B., Cuchurat M., Buchmuller A., Juillard-Delsart D., and Decousus H. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 831 (2000) 14-19
4. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., and Ray G. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 338S-400S
5. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., and Kelton J.G. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
6. Bhandari M., Hirsh J., Weitz J., Young E., Venner T.J., and Shaughnessy S.G. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 80 (1998) 413-417
7. Hirsh J., and Levine M.N. Low molecular weight heparin. Blood 79 (1992) 1-17
8. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
9. Mahe I., Aghassarian M., Drouet L., Dit-Sollier C.B., Lacut K., Heilmann J.J., Mottier D., and Bergmann J.F. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 97 (2007) 581-586
10. Lim W., Dentali F., Eikelboom J.W., and Crowther M.A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144 (2006) 673-684
11. Cook L.M., Kahn S.R., Goodwin J., and Kovacs M.J. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 5 (2007) 937-941
12. Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., Kusek J.W., and Van Lente F. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006) 247-254
13. Cockcroft D.W., and Gault M.N. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
14. Levey A.S., Coresh J., Balk E., Kausz A.T., Levin A., Steffes M.W., Hogg R.J., Perrone R.D., Lau J., and Eknoyan G. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
15. Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. Arch Intern Med 158 (1998) 1855-1868
16. Lovenox (enoxaparin sodium injection). Product monograph (March 17, 2006), Sanofy-Aventis Pharma Inc, Laval, QB
17. Fraxiparine (nadroparin calcium injection). Product monograph (February 12, 2007), GlaxoSmithCline Inc, Mississauga, ON
18. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
19. Sanderink G.J., Guimart C.G., Ozoux M.L., Jariwala N.U., Shukla U.A., and Boutouyrie B.X. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 105 (2002) 225-231
20. Tincani E., Mannucci C., Casolari B., Turrini F., Crowther M.A., Prisco D., Cenci A.M., and Bondi M. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 91 (2006) 976-979
21. Goldhaber S.Z., Dunn K., and MacDougall R.C. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 118 (2000) 1680-1684
22. Ageno W., Squizzato A., Ambrosini F., Dentali F., Marchesi C., Mera V., Steidl L., and Venco A. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 87 (2002) 746-750
23. Stratton M.A., Anderson F.A., Bussey H.I., Caprini J., Camerota A., Haines S.T., Hawkins D.W., O'Connell M.B., Smith R.C., and Stringer K.A. Prevention of venous thromboembolism: adherence to 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 160 (2000) 334-340
24. Kahn S.R., Panju A., Geerts A., Pineo G.F., Desjardins L., Turpie A.G.G., Glezer S., Thabane L., and Sebaldt R.J. for the CURVE Study Investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 119 (2007) 145-155
25. Dentali F., Douketis J.D., Gianni M., Lim W., and Crowther M.A. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 146 (2007) 278-288